Polypharmacy in antipsychotic pharmacological treatment among patients with dual diagnosis in Denmark

References

• Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(7):830–842. doi: 10.1001/archpsyc.64.7.830.
   PubMed Web of Science ®Google Scholar
• Hasin DS, Grant BF. The national epidemiologic survey on alcohol and related conditions (NESARC) waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol. 2015;50(11):1609–1640. doi: 10.1007/s00127-015-1088-0.
   PubMed Web of Science ®Google Scholar
• Drake RE, Brunette MF. Complications of severe mental illness related to alcohol and drug use disorders. Recent Dev Alcohol. 1998;14:285–299.
   PubMedGoogle Scholar
• Smith RL, Tveito M, Kyllesø L, et al. Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs − a study based on blood sample analyses from 24,239 patients. Eur Neuropsychopharmacol. 2020;37:64–69. doi: 10.1016/j.euroneuro.2020.06.007.
   PubMed Web of Science ®Google Scholar
• Han B, Compton WM, Blanco C, et al. Prevalence, treatment, and unmet treatment needs of US adults with mental health and substance use disorders. Health Aff. 2017;36(10):1739–1747. doi: 10.1377/hlthaff.2017.0584.
   PubMed Web of Science ®Google Scholar
• Benjaminsen L, Enemark EM. Brug af velfærdssystemet blandt borgere med misbrug – En registerbaseret analyse af de samfundsøkonomiske aspekter af stof- og alkoholmisbrug. VIVE – Viden til Velfærd - Det Nationale Forsknings- og Analysecenter for Velfærd. Copenhagen. 2020.
   Google Scholar
• Kamei H. Polypharmacy management of antipsychotics in patients with schizophrenia. Medicina (Kaunas). 2022;58(11):1584. doi: 10.3390/medicina58111584.
   PubMed Web of Science ®Google Scholar
• Pae C-U, Han C, Bahk W-M, et al. Consideration of long-acting injectable antipsychotics for polypharmacy regimen in the treatment of schizophrenia: put it on the table or not? Clin Psychopharmacol Neurosci. 2021;19(3):434–448. doi: 10.9758/cpn.2021.19.3.434.
   PubMed Web of Science ®Google Scholar
• Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168(7):702–708. doi: 10.1176/appi.ajp.2011.10060908.
   PubMed Web of Science ®Google Scholar
• Ayani N, Morimoto T, Sakuma M, et al. Antipsychotic polypharmacy is associated with adverse drug events in psychiatric inpatients: the Japan adverse drug events study. J Clin Psychopharmacol. 2021;41(4):397–402. doi: 10.1097/JCP.0000000000001416.
   PubMed Web of Science ®Google Scholar
• Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18–28. doi: 10.1016/j.schres.2012.03.018.
   PubMed Web of Science ®Google Scholar
• Alberdi F, Storch Jakobsen A, Rasmussen J. Antipsychotic drug use in Greenland and Denmark: longitudinal and cross-sectional data. Nord J Psychiatry. 2022;76(3):189–194. doi: 10.1080/08039488.2021.1942981.
   PubMed Web of Science ®Google Scholar
• Sneider B, Pristed SG, Correll CU, et al. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: a nation-wide pharmacoepidemiological study. Eur Neuropsychopharmacol. 2015;25(10):1669–1676. doi: 10.1016/j.euroneuro.2015.04.027.
   PubMed Web of Science ®Google Scholar
• Højlund M, Andersen JH, Andersen K, et al. Use of antipsychotics in Denmark 1997–2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses. Epidemiol Psychiatr Sci. 2021;30:e28. doi: 10.1017/S2045796021000159.
   PubMed Web of Science ®Google Scholar
• Westaway K, Sluggett JK, Alderman C, et al. Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness. Int J Evid Based Healthc. 2016;14(3):104–112. doi: 10.1097/XEB.0000000000000082.
   PubMed Web of Science ®Google Scholar
• Farrell C, Brink J. The prevalence and factors associated with antipsychotic polypharmacy in a forensic psychiatric sample. Front Psychiatry. 2020;11:263. doi: 10.3389/fpsyt.2020.00263.
   PubMed Web of Science ®Google Scholar
• Mårtensson S, Johansen KS, Krarup J, et al. REDD-PAC cohort description: researching dual diagnosis - prognosis and characteristics. J Dual Diagn. 2022;18(2):111–122. doi: 10.1080/15504263.2022.2055250.
   PubMed Web of Science ®Google Scholar
• Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39–59. doi: 10.1007/s40263-020-00779-5.
   PubMed Web of Science ®Google Scholar
• Danish Medical Council. Baggrundsnotat for medicinsk behandling af psykotiske tilstande. 2013 27 June 2022]; Available from: https://www.regioner.dk/media/2133/psykotiske-tilstande-baggrundsnotat3.pdf.
   Google Scholar
• Baandrup L. Polypharmacy in schizophrenia. Basic Clin Pharmacol Toxicol. 2020;126(3):183–192. doi: 10.1111/bcpt.13384.
   PubMed Web of Science ®Google Scholar
• Dold M, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2012;11(11):Cd006391.
   PubMedGoogle Scholar
• Hasan A, Falkai P, Wobrock T, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–378. doi: 10.3109/15622975.2012.696143.
   PubMed Web of Science ®Google Scholar
• Japanese Society of Neuropsychopharmacology. Guideline for pharmacological therapy of schizophrenia. Neuropsychopharmacol Rep. 2021;41(3):266–324. doi: 10.1002/npr2.12193.
   PubMed Web of Science ®Google Scholar
• Baandrup L, Kruse M. Incident users of antipsychotics: who are they and how do they fare? Soc Psychiatry Psychiatr Epidemiol. 2016;51(4):505–512. doi: 10.1007/s00127-015-1129-8.
   PubMed Web of Science ®Google Scholar
• Iqbal MN, Levin CJ, Levin FR. Treatment for substance use disorder with co-occurring mental illness. Focus (Am Psychiatr Publ). 2019;17(2):88–97. doi: 10.1176/appi.focus.20180042.
   PubMedGoogle Scholar
• Cowi D, Thomsen LA. Evaluation of regional interdisciplinary teams regarding medication in psychiatry [Translated from Danish: evaluering af regionale tværfaglige teams vedrørende medicinering i psykiatrien]. 2019; 29 Sep. 2022]; 1–94. Available from: https://www.sst.dk/-/media/Udgivelser/2020/Evaluering-af-tvaerfaglige-medicinteams-i-psykiatrien.ashx?sc_lang=da&hash=8803D3CB72722DFD0F25ADA66CD398A6.
   Google Scholar
• IKAS. Definition of medication terms in DDKM for hospitals. 2nd version [Translate from Danish: definition af medicineringsbegreber i DDKM for sygehuse, 2.version]. 2014 29 Sep. 2022]; Available from: http://begrebsbasen.sst.dk/2014_medicinering/Arbejdspapirer/Definitioner%20af%20medicineringsbegreber%20i%20DDKM%20for%20sygehuse,%202.version%201.0.pdf.
   Google Scholar
• Tani H, Uchida H, Suzuki T, et al. Interventions to reduce antipsychotic polypharmacy: a systematic review. Schizophr Res. 2013;143(1):215–220. doi: 10.1016/j.schres.2012.10.015.
   PubMed Web of Science ®Google Scholar
• Thompson A, Sullivan SA, Barley M, et al. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards – a cluster randomized controlled trial. Psychol Med. 2008;38(5):705–715. doi: 10.1017/S003329170700147X.
   PubMed Web of Science ®Google Scholar
• Borlido C, et al. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2016;77(1):20580.
   Web of Science ®Google Scholar
• Horowitz MA, Jauhar S, Natesan S, et al. A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophr Bull. 2021;47(4):1116–1129. doi: 10.1093/schbul/sbab017.
   PubMed Web of Science ®Google Scholar
• Shah C, Sharma TR, Kablinger A. Controversies in the use of second generation antipsychotics as sleep agent. Pharmacol Res. 2014;79:1–8. doi: 10.1016/j.phrs.2013.10.005.
   PubMed Web of Science ®Google Scholar
• Crockford D, Addington D. Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry. 2017;62(9):624–634. doi: 10.1177/0706743717720196.
   PubMed Web of Science ®Google Scholar